Context: Uterine leiomyomas are the most common type of gynecologic tumor in women. Objective: To determine the role of the cytokine receptor activator of nuclear factor κ-Β ligand (RANKL); its receptor, receptor activator of nuclear factor κ-Β (RANK); and the RANKL/RANK pathway inhibitor RANK-Fc in leiomyoma growth. Design: Messenger RNA (mRNA) or protein levels of RANKL, RANK, and proliferation markers cyclin D1 and Ki67 were assessed in various leiomyoma tissues and cell populations. Human xenograft experiments were performed to determine the effects of RANK-Fc on leiomyoma growth in vivo. Setting: Research laboratory. Patients: Twenty-four regularly cycling premenopausal women (age 28 to 49 years) who were not receiving hormone therapy. Interventions: None. Main Outcome Measure: Tumor growth in a murine xenograft model following targeting of the RANKL/RANK pathway with RANK-Fc. Results: RANKL mRNA levels in leiomyoma were significantly higher than those in myometrial tissues. The highest RANK levels were found in the leiomyoma stem cell population, which is deficient in progesterone receptor (PR). Conversely, the highest RANKL levels were found in the PR-rich leiomyoma intermediate cell (LIC) population. R5020, a PR agonist, specifically increased RANKL expression in LICs. RANK-Fc blocked RANKL-induced expression of the proliferative gene cyclin D1. Treatment with RANK-Fc also significantly decreased tumor growth in vivo and diminished the expression of proliferation marker Ki67 in tumors (P < 0.01; n = 4). Conclusions: Treatment with the RANKL/RANK pathway inhibitor RANK-Fc significantly decreased human leiomyoma cell proliferation and tumor growth. This suggests that the RANKL/RANK pathway could serve as a potential target for the prevention and treatment of uterine leiomyoma.
Context: Uterine leiomyomas are the most common type of gynecologic tumor in women. Objective: To determine the role of the cytokine receptor activator of nuclear factor κ-Β ligand (RANKL); its receptor, receptor activator of nuclear factor κ-Β (RANK); and the RANKL/RANK pathway inhibitor RANK-Fc in leiomyoma growth. Design: Messenger RNA (mRNA) or protein levels of RANKL, RANK, and proliferation markers cyclin D1 and Ki67 were assessed in various leiomyoma tissues and cell populations. Human xenograft experiments were performed to determine the effects of RANK-Fc on leiomyoma growth in vivo. Setting: Research laboratory. Patients: Twenty-four regularly cycling premenopausal women (age 28 to 49 years) who were not receiving hormone therapy. Interventions: None. Main Outcome Measure: Tumor growth in a murine xenograft model following targeting of the RANKL/RANK pathway with RANK-Fc. Results:RANKL mRNA levels in leiomyoma were significantly higher than those in myometrial tissues. The highest RANK levels were found in the leiomyoma stem cell population, which is deficient in progesterone receptor (PR). Conversely, the highest RANKL levels were found in the PR-rich leiomyoma intermediate cell (LIC) population. R5020, a PR agonist, specifically increased RANKL expression in LICs. RANK-Fc blocked RANKL-induced expression of the proliferative gene cyclin D1. Treatment with RANK-Fc also significantly decreased tumor growth in vivo and diminished the expression of proliferation marker Ki67 in tumors (P < 0.01; n = 4). Conclusions: Treatment with the RANKL/RANK pathway inhibitor RANK-Fc significantly decreased humanleiomyoma cell proliferation and tumor growth. This suggests that the RANKL/RANK pathway could serve as a potential target for the prevention and treatment of uterine leiomyoma.
Authors: Peter G Whang; Edward M Schwarz; Seth C Gamradt; William C Dougall; Jay R Lieberman Journal: J Orthop Res Date: 2005-07-06 Impact factor: 3.494
Authors: Eden R Cardozo; Andrew D Clark; Nicole K Banks; Melinda B Henne; Barbara J Stegmann; James H Segars Journal: Am J Obstet Gynecol Date: 2011-12-11 Impact factor: 8.661
Authors: M A Lomaga; W C Yeh; I Sarosi; G S Duncan; C Furlonger; A Ho; S Morony; C Capparelli; G Van; S Kaufman; A van der Heiden; A Itie; A Wakeham; W Khoo; T Sasaki; Z Cao; J M Penninger; C J Paige; D L Lacey; C R Dunstan; W J Boyle; D V Goeddel; T W Mak Journal: Genes Dev Date: 1999-04-15 Impact factor: 11.361
Authors: H Hsu; D L Lacey; C R Dunstan; I Solovyev; A Colombero; E Timms; H L Tan; G Elliott; M J Kelley; I Sarosi; L Wang; X Z Xia; R Elliott; L Chiu; T Black; S Scully; C Capparelli; S Morony; G Shimamoto; M B Bass; W J Boyle Journal: Proc Natl Acad Sci U S A Date: 1999-03-30 Impact factor: 11.205
Authors: David L Lacey; William J Boyle; W Scott Simonet; Paul J Kostenuik; William C Dougall; John K Sullivan; Javier San Martin; Roger Dansey Journal: Nat Rev Drug Discov Date: 2012-05 Impact factor: 84.694
Authors: Erica E Marsh; Geraldine E Ekpo; Eden R Cardozo; Maureen Brocks; Tanaka Dune; Leeber S Cohen Journal: Fertil Steril Date: 2013-03-15 Impact factor: 7.329
Authors: Molly B Moravek; Ping Yin; Masanori Ono; John S Coon; Matthew T Dyson; Antonia Navarro; Erica E Marsh; Debabrata Chakravarti; J Julie Kim; Jian-Jun Wei; Serdar E Bulun Journal: Hum Reprod Update Date: 2014-09-08 Impact factor: 15.610
Authors: Ijeoma Okeigwe; Serdar Bulun; Shimeng Liu; Alfred W Rademaker; John S Coon; Stacy Kujawa; Jared Robins; Ping Yin Journal: J Clin Endocrinol Metab Date: 2019-12-01 Impact factor: 5.958
Authors: Phyllis C Leppert; Ayman Al-Hendy; Donna D Baird; Serdar Bulun; William Catherino; Darlene Dixon; Merrick Ducharme; Quaker E Harmon; Friederike L Jayes; Emmanuel Paul; Aymara Mas Perucho; James Segars; Carlos Simón; Elizabeth A Stewart; Jose Teixeira; Andrea Tinelli; Daniel Tschumperlin; Ami R Zota Journal: F S Sci Date: 2020-11-07
Authors: Shimeng Liu; Ping Yin; Jingting Xu; Ariel J Dotts; Stacy A Kujawa; John S Coon V; Hong Zhao; Ali Shilatifard; Yang Dai; Serdar E Bulun Journal: Endocrinology Date: 2020-10-01 Impact factor: 4.736